Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Relapsed/Refractory AML Clinical Trial

Official title:

A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05054543
• Other study ID #: APL-106-02
• Status: Recruiting
• Phase: Phase 3
• Start date: October 18, 2021
• Est. completion date: February 2024

Study information

• Verified date: September 2021
• Source: Apollomics Inc.
• Contact: Zhejiang CrownMab Ltd.
• Phone: 0571-83521933
• Email: ClinicalTrialsChina[@]apollomicsinc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Description:

This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at the time of randomization with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy as described.

Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (<60, ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse>6 months) and prior HSCT status. Treatment assignment received at randomization will be maintained during all induction and consolidation cycles.

This trial will have the following sequential phases: screening, baseline, induction treatment and count recovery, response assessment, consolidation treatment (if remission is achieved), and follow-up for relapse and survival assessment. Subjects not achieving remission will continue to be followed for long-term trial endpoints such as disease progression and survival. Blinding will be maintained until database lock. All subjects will be followed for long-term outcomes until death or withdrawal of consent.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: February 2024
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. =18 years and =75 years in age

2. AML diagnosed with =20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis

3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

1. For relapse AML, it must be the first or second relapse, and remain untreated.

2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.

4. No more than one prior stem cell transplant

5. Has not received the chemotherapy regimen to be used for induction on this trial

6. Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

Exclusion Criteria:

1. Patients with acute promyelocytic leukemia

2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)

3. Chronic myeloid leukemia with myeloid blast crisis

4. Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required)

5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.

6. Stem cell transplantation =4 months prior to dosing.

7. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing

8. Inadequate organ function.

9. Abnormal liver function.

10. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.

11. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).

12. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.

13. Clinically significant cardiovascular disease.

14. Major surgery within 4 weeks of dosing.

Related Conditions & MeSH terms

• Relapsed/Refractory AML

Intervention

Drug:
• Uproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
• Placebo
0.9% Sodium Chloride

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhejiang University	Hangzhou
China	Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Tianjin	Tianjin

Sponsors (2)

Lead Sponsor	Collaborator
Apollomics Inc.	Zhejiang CrownMab Biotech Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Time from the date of randomization into the study to the date of death.	3 years
Secondary	Remission rate(rate of CR, CR/CRi and CR/CRh)	Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh	Up to 60 days
Secondary	Duration of remission	Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.	Up to 3 years
Secondary	Event-free survival	Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.	Up to 3 years
Secondary	Rate of severe oral mucositis	Incidence of severe oral mucositis experienced in patients after treatment.	Up to 254 days